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Abstract: 54 
Background: In the emergency of the SARS-CoV-2 pandemic, great efforts were made to quickly 55 
provide serology testing to the medical community however, these methods have been introduced into 56 
clinical practice without the complete validation usually required by the regulatory organizations.  57 
Methods: SARS-CoV-2 patient samples (n=43) were analysed alongside pre-pandemic control specimen 58 
(n=50), confirmed respiratory infections (n=50), inflammatory polyarthritis (n=22) and positive for 59 
thyroid stimulating immunoglobulin (n=30). Imprecision, diagnostic sensitivity and specificity and 60 
concordance were evaluated on IgG serologic assays from EuroImmun, Epitope Diagnostics (EDI), 61 
Abbott Diagnostics and DiaSorin and a rapid IgG/IgM test from Healgen. 62 
Results: EDI and EuroImmun imprecision was 0.02-14.0% CV. Abbott and DiaSorin imprecision (CV) 63 
ranged from 5.2% - 8.1% and 8.2% - 9.6% respectively. Diagnostic sensitivity of the assays were 100% 64 
(CI: 80-100%) for Abbott, EDI and EuroImmun and 95% (CI: 73-100%) for DiaSorin at ≥14 days post 65 
PCR. Only the Abbott assay had a diagnostic specificity of 100% (CI: 91-100%). EuroImmun cross-66 
reacted in 3 non-SARS-CoV-2 respiratory infections and 2 controls. The DiaSorin displayed more false 67 
negative results and cross-reacted in six cases across all conditions tested. EDI had one cross-reactive 68 
sample. The Healgen rapid test showed excellent sensitivity and specificity. Overall, concordance of the 69 
assays ranged from 76.1% to 97.9%.  70 
Conclusions: Serological tests for SARS-CoV-2 showed good analytical performance. The head-to-head 71 
analysis of samples revealed differences in results that may be linked to the use of nucleocapsid or spike 72 
proteins. The point of care device tested demonstrated adequate performance for antibody detection. 73 
 74 
  75 
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Introduction 76 
The scientific community has had to rapidly develop and manufacture tests for the new SARS-CoV-2 77 
pandemic at unprecedented speed, taking three months to develop assays that would ordinarily take three 78 
years. Serology testing, that can identify those who have previously been exposed to the SARS-CoV-2 79 
virus and have mounted an immune response, has been hailed as key to managing the pandemic however 80 
controversy remains over both the accuracy and utility of serology testing in disease management. 81 
Structural proteins, including the spike (essential for viral infection) and the nucleocapsid (important for 82 
viral RNA transcription), are both potential targets for early detection of infection and known to elicit an 83 
immune response in the host (1) with antibodies detectable within 20 days of disease onset (2–4).   84 
Systematic reviews (5,6) challenged the diagnostic accuracy of serological tests, particularly when using 85 
lateral flow immunoassays (LFIAs). Public Health England (PHE) showed only the Siemens and the 86 
Roche Diagnostics assays met the minimum UK Medicines and Healthcare products Regulatory Agency 87 
Target Product Profile criteria for sensitivity (7) after the threshold of positivity was adjusted to 0.128. 88 
Assays from DiaSorin and Abbott Diagnostics (8) also provided acceptable diagnostic results. These 89 
evaluations did not address cross-reactivity. To our knowledge little has been done regarding interference 90 
from antibodies produced during other viral infection and autoimmune disorders. Additionally, with the 91 
focus on diagnostic sensitivity and specificity, little has been done to evaluate the analytical accuracy, 92 
which if poor, has the potential to negate all of these study findings. Indeed in the editorial, Duong and 93 
colleagues clearly states that there is a need for critical independent evaluations of these tests, using the 94 
same specimen panels(9).  95 
This study provides a head-to-head evaluation of the diagnostic and analytical performance of four 96 
commercially available IgG based serology assays for SARS-CoV-2 and a diagnostic accuracy study of 97 
one point of care LFIA. 98 
 99 
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Material and methods 100 
Specimen collection and storage 101 
Patients were not involved in any part of the work. All samples were from archived specimens and were 102 
fully anonymized before we accessed them. Therefore, our study is in accordance with the blanket Ethical 103 
standards of University of East Anglia on de-identified samples for method development. Moreover, 104 
using the UK NHS Research Ethics Committee decision toolkit (http://www.hra-105 
decisiontools.org.uk/ethics/) we confirmed that separate ethical review was not required for this study 106 
which is in concordance with the Helsinki Declaration. 107 
All serum samples were collected, anonymized, aliquoted and stored at –80oC until analysed. SARS-108 
CoV-2 PCR-positive patients (AusDiagnostics platform, Chesham, UK) were of both genders, age range 109 
66 to 93 and hospitalized at the Norfolk and Norwich University Hospital (NNUH) or Queen Elizabeth 110 
Hospital in King Lynn (QEH). Samples were taken 8-44 days after testing positive for SARS-CoV-2. 111 
Negative control samples were collected in 2018 from patients with no history of infection or immune 112 
disorder. Pre-pandemic samples from patients who had a range of confirmed respiratory infections 113 
(including Influenza A, B and seasonal coronaviruses [Table 1]), samples collected from patients with 114 
inflammatory polyarthritis positive for anti-cyclic citrullinated peptide antibodies (anti-CCP) along with 115 
samples positive for thyroid stimulating immunoglobulin (TSI) were used to test the non-specific binding 116 
of non-SARS-CoV-2 antibodies. These groups of samples are referred to as N (negative control), CR 117 
(cross-reactivity), RA (Rheumatoid Arthritis), TSI (patients with thyroid stimulating immunoglobulin) 118 
and P (SARS-CoV-2 Positive). A total of 195 individual serum samples (43 P, 50 N, 50 CR, 22 RA and 119 
30 TSI) were analysed for SARS-CoV-2 IgG antibodies. For a subset of patients, samples were available 120 
for a series of time-points thus allowing for a time course analysis (43 patients, 142 samples).  121 
 122 
Study design 123 
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SARS-CoV-2 IgG immunoassays were from 1) Epitope Diagnostics Inc. (EDI, San Diego, CA, USA) 124 
performed using the Agility ELISA automate (Dynex Technologies, Chantilly, VA, USA), 2) EuroImmun 125 
UK ITC (UK) performed manually, 3) Abbott Diagnostics (Maidenhead, UK) on the Alinity™ i analyser 126 
and 4) DiaSorin (London, UK) on the Liaison XL analyser. A subset of samples were also tested using 127 
the point of care testing (POCT) device SARS-CoV-2 IgG/IgM rapid test from Healgen (Houston, TX, 128 
USA). Due to a limited number of cassettes available, 49 samples from 27 P were analysed along with 3 129 
N, 8 CR, 4 RA and 4 TSI. Cross-reactive and negative samples were primarily chosen from patient 130 
samples proven positive for seasonal coronaviruses and influenza A or a false positive result in one or 131 
more of the immunoassays. We focused on the IgG results in order to compare with the immunoassays. 132 
Assays were performed by trained biomedical scientists using manufacturer’s instructions. The SARS-133 
CoV-2 Abbott assay was performed in the clinical biochemistry department at NNUH and the other 134 
SARS-CoV-2 assays were performed at the University of East Anglia. All other non- SARS-CoV-2 135 
related tests were performed at the NNUH virology department. DiaSorin SARS-Cov-2 is a quantitative 136 
assay and antibody concentrations are expressed in AU/mL. The Abbott, EDI and EuroImmun are 137 
qualitative assays for which the result is calculated using the ratio of the sample optical density (OD) 138 
against the negative or calibrator control (Supplemental Table).  EuroImmun and DiaSorin assays detect 139 
antibodies to, respectively, recombinant S1 and S1/S2 domains of the SARS-CoV-2 spike protein while 140 
both the EDI and Abbott assay detect antibodies to the nucleocapsid. The POCT from Healgen is a solid 141 
phase lateral flow immunochromatographic assay (LFIA) for detection of SARS-CoV-2 of IgG and IgM, 142 
antigen not specified.  143 
 144 
Imprecision 145 
As the results are expressed with a values correlating with the amount of antibody detectable, imprecision 146 
was assessed using a Clinical and Laboratory Standards Institute (CLSI) EP-15 based protocol on the 147 
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automated clinical laboratory analysers protocol (34). Positive and negative patient pools and/or controls 148 
of different concentrations were prepared and frozen as aliquots and assayed as 5 replicates per day on 5 149 
different days. For the plate based assays, inter- and intra-assay CVs were calculated. Intra-assay was 150 
determined using the CV of the optical density (OD) of duplicated samples. Inter-assay was determined 151 
using the CV obtained from the sample pool and the kit positive control across the plates. 152 
 153 
Statistics 154 
Using IBM SPSS Statistics 25.0.0.1, Mann-Whitney and Cohen’s Kappa tests were used to compare OD 155 
results between groups and to determine the concordance between the assays, respectively. Analysis of 156 
EP15 was performed using EP evaluator. Variation was estimated on calculated values (R) or response 157 
(Relative Light Unit, RLU) as intra and inter-assay coefficient of variation (CV). Graphical 158 
representations were conducted with GraphPad Prism version 8.0 (GraphPad Software, Inc., USA). 159 
Throughout the tables, figures, and legends, the following terminology is used to show statistical 160 




Abbott EP15 and was performed on two Alinity analysers (Table 2). Overall, negative pool imprecision 165 
was CV=8.1% and 6.8% on equipment 1 and 2 respectively. Positive pool imprecisions were CV=2.3% 166 
and 1.1% respectively.  167 
DiaSorin EP15 imprecision was estimated based on response intensity (RLU). Positive control 168 
imprecision was between 8.2% and 13.8% (Table 2). The negative quality control material results were 169 
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consistently below the lower limit of detection of 3.8AU/mL and the negative pool concentration was 170 
consistently below 10AU/mL, the resulting calculated imprecision was therefore expectedly elevated. 171 
EDI and EuroImmun Intra-assay imprecision on duplicate samples (Table 2) was on average CV= 172 
3.3±3.8% and 6.1±6.7% respectively. Inter-assay imprecision of EDI was CV=14.2% for the kit positive 173 
pool and 16.5% for the negative pool. Baseline OD varied between the plates increasing the inter-assay 174 
variations, however, the ratio positive/cut-off was on average 1.43 ±0.16 (CV =11.1%). Inter-assay of 175 
EuroImmun was evaluated using the positive kit QC, the calibrator and the negative kit control. 176 
Coefficient of variation were CV = 12.9%, 9.5% and 3.7% respectively. 177 
 178 
Specificity and sensitivity 179 
A total of 43 individual P were analysed for SARS-CoV-2 IgG antibodies. Of these, twenty had samples 180 
taken at least 14 days after a positive PCR result (P≥14) and 23 were taken prior (P<14). All P≥14 had 181 
detectable antibodies in the EDI, EuroImmun, Abbott and Healgen assays. However, one sample returned 182 
a negative result using the DiaSorin assay. These results suggest a true positive rate of 100% with EDI, 183 
EuroImmun, Abbott and Healgen assays and 95% for the DiaSorin assay. 184 
Amongst the 23 P<14 samples, antibodies were detected for 65% (Abbott & EuroImmun), 61% (EDI) and 185 
43% (DiaSorin) of the samples. Two samples R were close to the threshold in EDI and Abbott (EDI: 0.8 186 
and Abbott 1.9; EDI: 1.0 and Abbott 0.8) resulting in one being positive in one assay and negative in the 187 
other (and vice-versa). 188 
All 50 N were negative on the Abbott and EDI. Two samples were positive and 48 were negative on the 189 
EuroImmun (although 2 were equivocal). Two false positive samples were also observed on the DiaSorin, 190 
one being positive on both DiaSorin and EuroImmun assays. 191 
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The IgG kits showed a very good diagnostic ability to differentiate between P and N (Table 3). Overall, 192 
EuroImmun and DiaSorin showed lower sensitivity and specificity than EDI and Abbott. Sensitivity 193 
ranged between 81-100% on all time points for EDI, EuroImmun and Abbott. DiaSorin sensitivity was 194 
71% on all time points and 95% for P≥14. Specificity was consistently 100% for the Abbott while it 195 
ranged between 92 to 100% for the other assays. 196 
 197 
Cross-Reactivity 198 
There were no SARS-CoV-2 IgG positive results from patients with non-SARS-CoV-2 infection (CR, 199 
n=50, including seasonal flu (n=7)), anti-CCP positive (RA, n=22) nor TSI positive (n=30) using the 200 
Abbott and the EDI assays. Overall, DiaSorin showed the highest (4%) cross-reactivity (2CR, 1 RA and 1 201 
TSI), followed by EuroImmun (3% - 3CR) and EDI (1% - 1 TSI). The Mann-Whitney test showed that on 202 
the EDI only, the R value of samples used to test cross-reactivity (RA and TSI) was significantly 203 
elevated, however only one sample was falsely positive for SARS-CoV-2 (Figure 1).  204 
Any sample that gave a false positive result in any of the immunoassays was also tested on the Healgen 205 
POCT and none were IgG positive. However, a very weak signal could be detected on one TSI sample 206 
and one sample from a patient with seasonal flu. Because of the very small number of sample tested, 207 
specificity calculation was not performed for the rapid test. 208 
 209 
Time course analysis  210 
We analysed 1 to 13 data points for 43 P. We observed an increase of the signal for presence of IgG over 211 
time going from negativity to positivity and reaching a plateau (Figure 2). Sigmoid curve-fitting indicated 212 
a time from PCR to seroconversion at 9.8 days (95% CI 10.7-13.7), 10.2 (95% CI 8.5-11.8), 12.2 days 213 
(95% CI 10.7-13.7) and 10.4 days (95% CI 7.9-12.9) for EDI, Abbott, DiaSorin and EuroImmun assays 214 
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respectively. Note that due to a limited number of EuroImmun tests available, we only had measurements 215 
for 56 (of 142) data points. One data point was missing for Abbott and 4 were missing for DiaSorin due to 216 
insufficient sample volume. 217 
We tested 48 samples from 27 P patients using the Healgen rapid test. Ninety four percent (n=45) 218 
displayed a positive test for IgG. Samples showed positive results with POCT from day 7 post PCR 219 
although these were still negative in the other immunoassays (SARS-CoV-2 positive at day 12).  220 
 221 
Assay Concordance 222 
Abbott and EDI had the greatest concordance with Cohen’s Kappa of 0.957 and 97.9% agreement 223 
between the all results (Table 4). DiaSorin was the most different, with agreements below 95%. The 224 
Healgen POCT concordance with the other assays was low (below 90%) but reflect a limited number of 225 
samples and may not be representative. Modifying the threshold to 0.8 for EDI would allow the detection 226 
of 2 more P<14 without increasing the rate of false positive. No change in threshold in the other assay 227 
would reclassify any results without dramatically affecting the specificity to either have a high rate of 228 
false positive or false negative.  229 
 230 
Discussion 231 
Statement of principal findings 232 
In this head to head study we demonstrated the good performance of four commercially available 233 
serologic assays for SARS-CoV-2 and one POCT. Abbott, Epitope Diagnostics Ltd and EuroImmun 234 
demonstrated higher sensitivity and specificity than the DiaSorin assay on the same specimens. The 235 
Abbott assay showed no cross-reactivity to any other potential interfering substances tested while EDI, 236 
EuroImmun and DiaSorin cross-reacted in 1%, 3% and 4% of the sample tested. However, no assay 237 
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cross-reacted with Influenza A and B or other coronaviruses. The analytical performance was deemed 238 
acceptable although it varied considerably between the different methods.  239 
 240 
It is estimated that there are nearly 300 different SARS-CoV-2 antibody tests in development globally 241 
ranging from POCT through to assays on large clinical laboratory analysers. Whilst data is accruing on 242 
the sensitivity and specificity of a number of these assays (5,6) there are still many with little or no 243 
published, independent performance evaluations. Whilst there is a focus on the diagnostic accuracy of 244 
these tests, much less is understood about the analytical performance of these devices such as imprecision 245 
and cross reactivity with common respiratory illnesses or immunoassay interferences. Without this 246 
knowledge the sensitivity and specificity data is brought into question and it is important that the 247 
limitations of assay are fully understood before applying the results in clinical practice. The Food and 248 
Drug Administration and European Medicines Agency acceptance criteria for biological assays typically 249 
define the required between-run and within-run precision as CV≤15 % for positive samples and ≤20 % for 250 
samples at the lower limit of quantification (10,11). All immunoassays passed the criteria for positive 251 
samples. 252 
Published median seroconversion time for IgG is around 14 days post symptoms (12–14). As we did not 253 
have access to symptom onset for most patients, we used PCR day to date the samples, before and after 254 
day 14. All samples post day 14 were positive in all assay except DiaSorin, which returned one false 255 
negative (day 39). Positivity prior to day 14 was consistent between EDI, EuroImmun and Abbott. These 256 
results are differing from those published by PHE who observed more false negative results in the Abbott 257 
than the DiaSorin (92.7% sensitivity vs 95% sensitivity, respectively) (8). We estimated seroconversion 258 
post PCR positivity to be between 9 and 12 days on these assays. Although we couldn’t do a full 259 
comparison of the POCT with the immunoassays, 100% of the P≥14 samples were IgG positive. More 260 
samples were also positive with POCT prior day 14 than in the other assays. 261 
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In regard to the POCT, our study showed excellent sensitivity and specificity. We observed no false 262 
negative results on P≥14 after a positive SARS-CoV-2 PCR and more samples were IgG positive P<14 263 
than the other immunoassays. Two potential false positive were detected (including seasonal flu) but the 264 
signal was very weak and confirmation would be necessary. The results of systematic reviews on point-of 265 
care serological tests for SARS-CoV-2 suggest discontinuing the use of the devices due to low sensitivity 266 
(5). Our results tend to reveal a different pattern however we only performed a limited number of tests. 267 
We chose 50 samples collected in 2018 from patients with no known infection as negative controls. Both 268 
the EDI and the Abbott showed 100% specificity. However, EuroImmun and DiaSorin produced false 269 
positives (n=4 and 2, respectively). Only one of these samples was common between both assays. PHE 270 
also showed lower specificity of the DiaSorin assay (vs Abbott). We analysed 50 samples from patients 271 
(pre-pandemic) presenting with respiratory infection. Among those 7 had the seasonal flu, 8 had influenza 272 
A., other viruses included EBV, Varicellazoster virus, parainfluenza, Adenovirus. EDI and Abbott 273 
showed 100% specificity with no false positive; however, we observed 3 positive results with the 274 
EuroImmun, two of these also being positive with the DiaSorin. These samples were from patients with 275 
EBV (n=1) and RSV (n=2). Our results on EuroImmun differ slightly from a previous evaluation (15), 276 
where specificity of the assay was excellent as early as 4 days after positive PCR and only 2 of 28 277 
samples showed borderline cross-reactivity to common human coronaviruses. None of the assays showed 278 
cross-reactivity either to the seasonal CoV flu or to Influenza A. Although it is based on a small number 279 
of sample (n=7 for each), it brings confidence that assays will be able to discriminate SARS-CoV-2 280 
antibodies during the next seasonal flu. Tang et al., showed similar results on 5 patients using EuroImmun 281 
and Abbott Assay (16). A great variety of endogenous substances such as polyreactive antibodies or 282 
autoantibodies, can interfere with the reaction between analyte and reagent antibodies in immunoassays. 283 
Assays for SARS-CoV-2 are no exception. Manufacturers, and evaluation studies to date, offer a limited 284 
insight into cross-reactivity of other antibodies in particular to other SARS-CoV antibodies(17–21). A 285 
small independent study showed no cross-reactivity was seen for patients with Influenza A (n=2), 286 
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Influenza B (n=2) and other coronaviruses (n= 5) (16). Samples with potentially interfering antibodies did 287 
not cross-react in the Abbott Diagnostics assay, and a limited number cross-reacted in the other assays. 288 
None of these samples was common between the different assays and modification of the various 289 
threshold would not improve performance of any assay.  290 
Successful attempts to treat SARS-CoV-2 patients with blood from convalescent individuals suggest 291 
antibodies against SARS-CoV-2 may have the ability to confer protective immunity to the disease (22–292 
27). Spike proteins are the most likely target for neutralizing antibodies are displayed on the surface of the 293 
virus whereas the nucleocapsid is contained within the viral envelope(28,29). Antibodies against the 294 
nucleocapsid have been shown to appear first (30,31), followed by the production of antibodies against 295 
the spike protein (12,13). Therefore, assays based on the nucleocapsid detection appear to be more 296 
sensitive early on in the disease recovery but presence of anti-S1/S2 antibodies may indicate presence of 297 
neutralizing antibodies. Both the EuroImmun and the DiaSorin are targeted the spike protein of SARS-298 
Cov-2 while the EDI and Abbott are targeted to the nucleocapsid protein of the virus. We observe a 299 
highest specificity of both nucleocapsid assays (EDI and Abbott, 100% (91-100%)) compared to the two 300 
spike assays (DiaSorin (96% (85-99%)) and EuroImmun (92% (79-97%)). Although the EuroImmun 301 
assay had the same sensitivity (all time points to PCR) as the EDI and Abbott, the DiaSorin assay was 302 
less sensitive (71% (73-100%) vs (81% (66-91%)), potentially supporting this hypothesis. 303 
Overall, the assays had high concordance, DiaSorin being the least identical to the others, with higher 304 
false negative and false positive, and lower performance. This is in accordance with the high false 305 
positive rate observed by Boukli et al. (32) with the DiaSorin Liaison SARS-CoV-2 IgG assay on patients 306 
with non-SARS-CoV-2 acute infections. The same samples were analysed on the different platforms and 307 
therefore the direct comparison is possible. However, one needs to consider the potential variance in 308 
antigen as the Wuhan strain has evolved as geographic spread has occurred between the different regions 309 
of the globe (GISAID) (33) and it is possible that these differences will not be seen on a different set of 310 
samples. Harmonization of the assays is necessary but will be near impossible with such variation 311 
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between assay designs (spike vs nucleocapsid). The Wales External Quality Assessment Scheme 312 
(WEQAS, UK, https://www.weqas.com/) is now offering a SARS-CoV-2 antibody external quality 313 
assessment (EQA) program for laboratories which will reduce uncertainty associated with different 314 
methods. 315 
 316 
Conclusion and policy implications 317 
The role of serology testing in the management of people with SARS-CoV-2 infection will remain 318 
controversial until we have clear data that enables an understanding of how production of IgG relates to 319 
immunity over time and whether or not the presence or absence of antibodies can inform risk of future 320 
infection. Whilst the clinical utility of serology tested is debated, it is important that the diagnostic and 321 
analytical performance of these tests is understood and adequate for need so that there can be confidence 322 
in the results when a meaningful clinical use is determined. Without high quality analytical testing the 323 
clinical application of serology testing in the future is not viable.  324 
This study examines the performance of four commercially available serologic assays for SARS-CoV-2 325 
in a head to head study. Our study demonstrated good analytical performance for all of the assays, 326 
however we observed Abbott, EDI and EuroImmun demonstrated higher sensitivity and specificity than 327 
the DiaSorin assay in this study. Whilst a full evaluation was not possible the P14+ samples from the 328 
main study were used in a sub analysis using the Healgen POCT device which showed 100% specificity, 329 
this contradicts earlier studies (5,6) and indicates that the evolution of the quality of POC devices has 330 
been rapid and some may now demonstrate adequate performance for antibody detection.  331 
Assays showed 0-4% cross-reactivity, however none with Influenza viruses. This may give increase 332 
confidence of the test during the seasonal flu period. We observed differences between the assay 333 
responses with DiaSorin being the most different from the other three. We hypothesize that these 334 
differences may be linked to the design of the assay themselves (spike glycoprotein or nucleocapsid) and 335 
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the timeline of production of antibodies for either antigen. We also suggested the possibility that the 336 
antigen plasticity and the antigen used when the manufacturer set up the test may influence the sensitivity 337 
of the CoV-2 assays. These findings highlight the importance of following the evolution of the antibody 338 
production and evolution of the virus over time. But it also highlights how harmonization of the assays 339 
will be complex.  340 
 341 
 342 
  343 
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Tables 449 
Table 1: Respiratory infections tested for cross reactivity in the SARS-CoV-2 IgG Immunoassays. 450 
Infection No patients 
Epstein-Barr virus  8 
Influenza A virus 8 
Respiratory syncytial virus 7 
Seasonal Coronaviruses 7 
Borrelia burgerdorferii 4 
Cytomegalovirus  3 
Varicellazoster virus 3 
Bordella Pertussis 2 
Hepatitis B  2 
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Table 2: EP15 analysis on two Abbott Alinity, DiaSorin Liaison XL and ELISAs imprecision tests. For 455 
the DiaSorin, negative samples (QC or pools) results were typically below the limit of detection of 3.8 456 
AU/mL and variation was estimated on the response in relative light units (RLU). 457 












 Alinity  1 (Neg) 25 0.136 (R) 0.011 8.1 0.011 8.1 
Alinity 1 (Pos) 25 7.254  (R) 0.167 2.3 0.170 2.3 
Alinity 2 (Neg) 25 0.143 (R) 0.007 5.2 0.010 6.8 








Kit Negative control 20 2457 (RLU) 1730 70.4 2860 116.4 
Level 1 (Neg pool) 25 6945 (RLU) 4003 57.6 5887 84.8 
Kit Positive control 25 58662 (RLU) 4815 8.2 5608 9.6 
Level 2 (Pool 1) 25 83236 (RLU) 11128 13.4 11128 13.4 
Level 3 (Pool 2) 25 410600 (RLU) 56802 13.8 56802 13.8 




Kit Negative control 27 0.074 (OD) - - 0.014 10.9 
Kit positive control 9 0.482 (OD) - - 0.068 14.2 










 Kit Negative control 3 0.074 (OD) - - 0.003 3.7 
Kit positive control 3 1.169 (OD) - - 0.15 2.9 
Calibrator 3 0.277 (OD) - - 0.027 9.5 
Duplicate samples 44 - 6.7 6.1 - - 
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Table 3: Sensitivity of the assays was estimated on all time points and including only samples >14 days 459 
post PCR. Specificity was estimated on pre-2020 samples (N) from healthy individuals and patients with 460 
disorders that induce the production of potentially interfering substances. n/a=no equivocal range 461 
available. 462 
  463 























Positive all time 
points 
EDI 43 35 8 n/a 81 (66-91) 
EuroImmun 43 35 8 0 81 (66-91) 
Abbott 43 35 8 n/a 81 (66-91) 
DiaSorin 42 30 12 0 71 (55-84) 
Healgen 27 27 0 n/a 100 (84-100) 
SARS-CoV-2 
Positive ≥14 days 
post PCR 
EDI 20 20 0 n/a 100 (80-100) 
EuroImmun 20 20 0 0 100 (80-100) 
Abbott 20 20 0 n/a 100 (80-100) 
DiaSorin 20 19 1 0 95 (73-100) 












EDI 50 0 50 n/a 100 (91-100) 
EuroImmun 50 2 46 2 92 (79-97) 
Abbott 50 0 50 n/a 100 (91-100) 
DiaSorin 50 2 48 0 96 (85-99) 
Healgen 4 0 4 n/a - 
Other Respiratory 
Infection (CR) 
EDI 50 0 50 n/a 100 (91-100) 
EuroImmun 50 3 47 0 94 (82-98) 
Abbott 50 0 50 n/a 100 (91-100) 
DiaSorin 50 2 48 0 96 (85-99) 
Healgen 9 1 8 n/a - 
Rheumatoid 
Arthritis (RA) 
EDI 22 0 22 n/a 92 (72-99) 
EuroImmun 22 0 22 0 92 (72-99) 
Abbott 22 0 22 n/a 100 (82-100) 
DiaSorin 22 1 21 0 95 (75-100) 
Healgen 4 0 4 n/a - 
Thyroid Disorder 
(TSI) 
EDI 30 1 29 n/a 97 (81-100) 
EuroImmun 30 0 28 2 93 (76-99) 
Abbott 30 0 30 n/a 100 (85-100) 
DiaSorin 30 1 29 0 97 (81-100) 
Healgen 4 1 3 n/a - 
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Table 4: Cohen’s Kappa concordance analysis of the assays and overall (all samples included) agreement 465 
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Figure Captions 472 
Figure 1: Box-plots of R values for each conditions (N, P, CR, RA and TSI) for the (A) EDI, (B) Abbott, 473 
(C) EuroImmun and (D) DiaSorin tests. Mann-Whitney analysis demonstrated a significant increase in the 474 
R value for the positive samples. Mann-Whitney statistical significance *p<0.05; **p<0.01 and 475 
***p<0.001. Dotted line represents the positive cut-off for each assay. 476 
 477 
 478 
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Figure 2: Seropositivity in specimen with PCR positive relative to day of PCR. Dashed line represent the 480 
cut-off ratio for each assay. Solid black line and dotted lines represent the 4 parameter logistic curve-fit of 481 
the points with confidence interval. Time to PCR onset is calculated as curve inflection point.  482 
